4 days ago · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. “This acquisition complements our strategy of … Continued

4 days ago · CHICAGO--(BUSINESS WIRE)--Feb. 3, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding …

3 days ago · Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. ... statements regarding Tempus’ acquisition of Ambry Genetics. In some cases ...

4 days ago · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

Nov 4, 2024 · Ambry Genetics has entered into a definitive agreement to be acquired by Tempus AI, a company advancing precision medicine through the practical application of artificial intelligence in healthcare.

3 days ago · CHICAGO–(BUSINESS WIRE)–Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.“This acquisition complements our strategy of leveraging ...

Mar 12, 2024 · Ambry Genetics, a leader in clinical diagnostic testing, and Tempus, a leader in artificial intelligence and precision medicine, announce a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

Nov 4, 2024 · The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Revenue increased 33.0% year-over-year to $180.9 million in the third quarter of 2024

Mar 12, 2024 · Tempus offers a comprehensive collection of genomic profiling solutions of solid tumor and liquid biopsy, along with algorithmic-based tests such as HRD and TO (tumor of unknown origin).

Nov 6, 2024 · Tempus AI agreed to buy genetic testing company Ambry Genetics for $375 million in cash and $225 million in shares. Chicago-based Tempus, which makes AI-enabled precision medicine solutions, said the purchase will provide expanded testing …